[Therapeutic advances with coxibs: few certainties and a lot of doubts]

Therapie. 2004 Mar-Apr;59(2):207-11. doi: 10.2515/therapie:2004040.

[Article in French]

Authors

Jean-Yves Jouzeau¹, Mikaël Daouphars, Patrick Netter

Affiliation

¹ Laboratoire de Pharmacologie et UMR 7561 CNRS-UHP, Faculté de Médecine de Nancy, Vandoeuvre-lès-Nancy, France. [email protected]

PMID: 15359614
DOI: 10.2515/therapie:2004040

No abstract available

Publication types

Review

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Celecoxib
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors / chemistry
Cyclooxygenase Inhibitors / therapeutic use*
France
Humans
Isoenzymes / genetics
Isoenzymes / metabolism*
Isoenzymes / physiology
Lactones / adverse effects
Lactones / chemistry
Lactones / therapeutic use
Membrane Proteins
Prostaglandin-Endoperoxide Synthases / genetics
Prostaglandin-Endoperoxide Synthases / metabolism*
Prostaglandin-Endoperoxide Synthases / physiology
Pyrazoles
Sulfonamides / adverse effects
Sulfonamides / chemistry
Sulfonamides / therapeutic use
Sulfones

Substances

Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Isoenzymes
Lactones
Membrane Proteins
Pyrazoles
Sulfonamides
Sulfones
rofecoxib
Cyclooxygenase 2
PTGS2 protein, human
Prostaglandin-Endoperoxide Synthases
Celecoxib